Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  CASI Pharmaceuticals, Inc.    CASI

CASI PHARMACEUTICALS, INC.

(CASI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
2.01(c) 2.21(c) 2.25(c) 2.51(c) 2.58(c) Last
156 120 519 430 515 504 772 160 1 504 151 Volume
+1.77% +9.95% +1.81% +11.56% +2.79% Change
More quotes
Financials (USD)
Sales 2020 14,7 M - -
Net income 2020 -42,2 M - -
Net cash position 2020 50,0 M - -
P/E ratio 2020 -6,75x
Yield 2020 -
Sales 2021 23,2 M - -
Net income 2021 -33,5 M - -
Net cash position 2021 32,8 M - -
P/E ratio 2021 -10,9x
Yield 2021 -
Capitalization 320 M 320 M -
EV / Sales 2020 18,4x
EV / Sales 2021 12,4x
Nbr of Employees 125
Free-Float 57,0%
More Financials
Company
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and... 
More about the company
Notations Surperformance© of CASI Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about CASI PHARMACEUTICALS, INC.
11/19CASI PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
11/19CASI PHARMACEUTICALS : Announces Partner Juventas Completes $65 Million Financin..
AQ
11/10CASI PHARMACEUTICALS : Announces Third Quarter 2020 Financial Results
AQ
11/09CASI PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Fina..
AQ
11/09CASI PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
11/06CASI PHARMACEUTICALS : to Report Third Quarter 2020 Financial Results and Host C..
AQ
10/29BioInvent Interim Report January 1 - September 30, 2020
AQ
10/28CASI PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financi..
AQ
10/27BIOINVENT INTERNATIONAL : Notice to Extraordinary General Meeting in BioInvent I..
AQ
10/05CASI PHARMACEUTICALS : Announces Poster Presentation at the 2020 AABB Virtual An..
AQ
09/30CASI PHARMACEUTICALS : Announces Restructuring of Partnership with Juventas Cell..
AQ
09/28CASI PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financi..
AQ
09/14CASI PHARMACEUTICALS : to Participate in Two Upcoming September Conferences
AQ
09/02CASI PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
08/19CASI PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K)
AQ
More news
News in other languages on CASI PHARMACEUTICALS, INC.

- No features available -

More news
Chart CASI PHARMACEUTICALS, INC.
Duration : Period :
CASI Pharmaceuticals, Inc. Technical Analysis Chart | CASI | US14757U1097 | MarketScreener
Technical analysis trends CASI PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 3,80 $
Last Close Price 2,58 $
Spread / Highest target 93,8%
Spread / Average Target 47,2%
Spread / Lowest Target 12,0%
EPS Revisions
Managers
NameTitle
Wei-Wu He Executive Chairman & Chief Executive Officer
Wei Zhang President & Chief Financial Officer
Cynthia Wong Hu COO, Secretary, Vice President & General Counsel
Alexander A. Zukiwski Chief Medical Officer
Zuie Chin Huang Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CASI PHARMACEUTICALS, INC.-16.50%320
LONZA GROUP AG55.66%44 931
MODERNA, INC.458.18%43 204
CELLTRION, INC.82.04%39 870
IQVIA HOLDINGS INC.9.94%32 568
SEAGEN INC.44.80%29 832